The basal ganglia, a group of nuclei, are associated with a variety of functions, including motor control. The striatum, which is the major input station of the basal ganglia in the brain, is regulated in part by dopaminergic input from the substantia nigra. The striatum is made up 96% of medium spiny neurons which are GABAergic cells. GABAergic cells are known to contain DA receptors which divide into two main branches- the D1 receptor (D1R)-expressing direct pathway and the D2 receptor (D2R)-expressing indirect pathway. The role of these two efferent pathways has not been clear in control of motor behaviors. To establish the influence of the different DA subtypes on GABAergic systems in the striatum, D1 selective receptor agonist (SKF 38393) and D2 selective receptor agonist (Quinpirole) were administered to mice. SKF 38393 and quinpirole were administered intraperitoneally in a volume of 0, 1, 5, 10 (mg/kg) and motor activity was assessed for 60 min immediately after the injection of DA agonists. Mice were sacrificed after behavioral test and the striatum in the brain were dissected for analysis of GABA level with HPLC. Both SKF 38393 and quinpirole dose-dependently increased locomotor activity but, GABA level in the striatum was clearly different in two agonists. These findings provide insight into the selective contributions of the direct and indirect pathways to striatal GABAergic motor behaviors.

**Key words:** basal ganglia, striatum, D1 & D2 agonist, locomotor, GABA
model of PD (Steg and Johnels, 1993; Redgrave et al., 2010). Thus, the nigrostriatal dopamine pathway in the basal ganglia is important for motor control and classical models of proposed two efferent pathways have not been clear in part of GABAergic striatal motor behavior. Here, we have explored whether GABAergic cells in the striatum are affected by specific excitation of D1 and D2 dopamine receptor subtypes and modulate locomotor activity.

**MATERIALS AND METHODS**

**Animals**

Male C57BL/6J male mice 7 weeks of age were obtained from the Orient Co. (Kyungki-Do, Korea), and they were housed for 1 week under a 12:12 h light-dark cycle in a temperature-controlled and humidity-controlled room. All animal care and testing conditions were in accordance with the IACUC (Institutional Animal Care and Use Committee) in College of Medicine, the Catholic University of Korea.

**SKF 38393 and quinpirole treatment**

Hydrochloride salts of SKF 38393 and quinpirole (LY 171555) were obtained from Sigma Aldrich (St. Louis, MO, USA). All drug doses were calculated as the free base and the drugs were dissolved in 0.9% saline vehicle. All the mice were received intraperitoneally.

**Behavioral measurements**

The locomotor activity was measured in a rectangular container (40×40×45 cm) that was equipped with a video camera above the centre of the floor as described previously (Chae et al., 2004). The walls and floor were made of clear plastic and they were painted with white. The locomotor activity was monitored by a video-tracking system using the SMART program (PanLab, Barcelona, Spain). Mice were allowed to adapt themselves for 1 h in the container and the distance they travelled was recorded every 10 min throughout a 1-h baseline and for 1 h after treatment. Locomotor activity was measured in cm.

**Sample collections and GABA measurements**

At the end of behavioral measurements, the striatums were dissected from the mice and all samples were frozen at −70 °C. GABA analysis was done using high performance liquid chromatography (HPLC). The mobile phase consisted of 40% acetonitrile in 20 mM sodium acetate buffer (pH 4.5 with glacial acetic acid) with a flow rate of 0.7 mL/min. Samples underwent pre-column derivatization with o-phthaldialdehyde (OPT), and were detected with a fluorescence detector (excitation 350 nm, emission 450 nm). Area was used to calculate results from a standard curve, with an internal standard (commercial γ-aminobutyric acid).

**Statistical analysis**

The experimental results are expressed as means±s.e. The behavioral data were analyzed using the SPSS program (Version 13.0). Statistical differences among groups were analyzed by one-way analysis of variance followed by the Tukey’s post-hoc and LSD technique. p<0.05 was considered to be significant.

**RESULTS AND DISCUSSION**

The present study explored whether locomotor activity and GABAergic cells in the striatum are affected by specific excitation of dopamine D1 and D2 receptor subtypes.

There was a dose-dependently (0, 1, 5 or 10 mg/kg) significant increase in the locomotor activity of the mice after treatment with SKF 38393 or quinpirole as seen in Fig. 1. Significant increases in activity were observed 10 min after injection of SKF 38393. The higher dose (SKF 38393 10 mg/kg) significantly increased activity at every time-point sampled over the 1hr test period [F(3,19) =18.307, p<0.001]. SKF 38393 is a synthetic compound...
which acts as a selective D1/D5 receptor partial agonist. Most of previous studies have reported that dopamine D1 receptor agonists are stimulating locomotor activity (Bruhwyler et al., 1991; Mazurski and Beninger, 1991). We observed a significant increase in locomotor activity of the mice injected with the dopamine D1 receptor agonist, SKF 38393, compared to control injected with vehicle. The results confirm previous studies indicating that D1 agonist predominantly increase locomotor activity (Molloy and Waddington, 1985 and 1987; Mazurski and Beninger, 1991). Also, dopamine D2 receptor agonist, quinpirole, significantly increases locomotor activity at 20 min after injecting quinpirole in dose dependent manner \( F(3,17) = 14.48, p < 0.001 \). But, the role of dopamine D2 receptors in the locomotor activity of adult animals is ambiguous. For example, administration of quinpirole led to dose-dependent (0.05~1.0 mg/kg) increase of locomotion consistent with the present result (Brown et al., 2002; Stuchik et al., 2007). However, in other studies, the effects of quinpirole in rodents have been shown to depend on dose and time after injection. At lower doses (0.1 mg/kg), decreases in activity are observed (Horvitz et al., 2001; Schindler et al., 2002) and at higher doses (0.5~10 mg/kg), increases in activity can be seen at 60 min after injection (Horvitz et al., 2001). The doses in the current study were in high range and activity was measured immediately following injection. Although biphasic pattern of quinpirole on locomotor inhibition followed by excitation is not clear, the results confirm that higher doses of D2 receptor agonist increase locomotor activity.

GABA levels in the striatum were clearly different in two agonists. GABA level induced by SKF 38393 was increased in the striatum \( F(3,16)=11.827, p<0.001 \) (Fig. 2) and GABA level induced by quinpirole was decreased \( F(3,16)=2.05, p=0.15 \) (Fig. 3). Thus, dopamine D1 receptor agonist appeared to exert increase in GABA release and dopamine D2 receptor agonist appeared to inhibit GABA release in the striatum. The study of Harsing and Zigmond (1997) demonstrated that the overflow of GABA evoked by electrical field stimulation (8 Hz) was decreased by SKF-38393 (10 microM), and electrically evoked GABA overflow was increased by quinpirole (10 microM) in the striatum. Thus, our results support previous studies indicating that dopamine agonist can exert an excitatory influence on GABA release via D1 receptor and an inhibitory influence on GABA release via D2 receptor within the striatum. The striatum, which is the major input station of the basal ganglia in the brain, is regulated in part by dopaminergic input from the substantia nigra. The striatum is made up 96% of medium spiny neurons which are GABAergic cells (Yelnik et al., 1991). Reduced dopamine innervation of the striatum results in hypokinesia and difficulty in initiating different motor patterns and enhanced striatal dopamine activity give rise to hyperkinesia (Blair, 2003; Grillner et al., 2005). These results provide inkling that the striatum has a important role in the selection of motor behavior (Grillner et al., 2005). The GABAergic cells have DA receptors which divide into two main branches - the D1 receptor (D1R)-expressing direct pathway and the D2 receptor (D2R)-expressing indirect pathway (Bateup et al., 2010). The direct pathway projects to the substantia nigra pars reticulata (SNpr) and the indirect pathway projects to the internal globus pallidus (GPe) and the STN (Gerfen et al., 1990). The striatal medium spiny output neurons are inhibitory (GABAergic). Striatal neurons are activated by dopaminergic innervations via D1 type receptors, it provides strong inhibition to the SNpr and thereby disinhibits thalamic neurons in a motor center which are responsible for releasing locomotor. In the indirect pathway from the striatum via the GPe and the STN, striatal neurons activated by dopaminergic innervations via D2 type receptors inhibit thalamic neurons in a motor center that affect motor behavior (DeLong and Wichmann, 2000).
2007). Actually, most of previous experiments have reported that dopamine D1 receptor agonists are stimulating locomotor activity (Bruhwyler et al., 1991; Mazurski and Beninger, 1991), however, the role of dopamine D2 receptors in the locomotor activity is ambiguous (Horvitz et al., 2001; Brown et al., 2002; Schindler et al., 2002; Stuchik et al., 2007). Thus, this behavioral hypothesis is needed to be further investigated. Parkinsonism resulted from the loss of nigrostriatal dopamine is a movement disorder characterized by tremor, hypokinesia, rigidity, and postural instability (Gerfen et al., 1990; DeLong and Wichmann, 2007). The study on PD has been greatly facilitated in the 1-methyl4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) primate model of the disease by using metabolic imaging and electrophysiological studies. The MPTP model has suggested that neuronal discharge is increased in the STN, GPi, and SNr but decreased in the GPe, thus resulting in excessive inhibition of components of the motor circuit in the thalamus, cortex, and brainstem. These aspects of the model are generally supported by lesioning and inactivation studies, which have shown that inactivation of the STN or GPi increases the metabolic activity in cortical motor areas and improves bradykinesia and tremor in patients with PD. However, lesions of the thalamus do not lead to significant bradykinesia or akinesia, and lesions of the GPI do not result in dyskinesias (DeLong and Wichmann, 2007). Although this issue is complex and still unsettled, nigrostriatal GABAergic pathway in the basal ganglia is important for motor control. Both SKF 38393 and quinpirole dose-dependently increased locomotor activity but, GABA level in the striatum was clearly different in two agonists. Our results provide insight into the selective control of the direct and indirect pathways to striatal GABAergic motor behaviors. Specific GABAergic motor control of the direct and indirect pathways in the basal ganglia requires further investigations which will contribute to therapeutic understanding of motor function disorders.

ACKNOWLEDGEMENTS

This work was supported by the Korea Research Foundation Grant funded by the Korean Government (KRF-2008-313-C00624).

REFERENCES

1. Bateup HS, Santini E, Shen W, Birnbaum S, Valjent E, Surmeier DJ, Fisone G, Nestler EJ and Greengard P (2010) Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 107:14845-14850.
2. Blair RJ (2003) Facial expressions, their communicatory functions and neuro-cognitive substrates. Philos Trans R Soc Lond B Biol Sci 358:561-572.
3. Brown RW, Gass JT and Kostrzewa RM (2002) Ontogenetic quinpirole treatments produce spatial memory deficits and enhance skilled reaching in adult rats. Pharmacol Biochem Behav 72:591-600.
4. Bruhwyler J, Chléide E, Liégeois JF, Delarge J and Mercier M (1991) Effects of specific dopaminergic agonists and antagonists in the open-field test. Pharmacol Biochem Behav 39:367371.
5. Chae Y, Yang CH, Kwon YK, Kim MR, Pyun KH, Hahm DH, Lee HJ and Shim I (2004) Acupuncture attenuates repeated nicotine-induced behavioral sensitization and c-fos expression in the nucleus accumbens and striatum of the rat. Neurosci Lett 358:87-90.
6. DeLong MR and Wichmann T (2007) Circuits and circuit disorders of the basal ganglia. Arch Neurol 64:20-24.
7. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr and Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432.
8. Grillner S, Hellgren J, Ménard A, Saitoh K and Wikström MA (2005) Mechanisms for selection of basic motor programs - roles for the striatum and pallidum. Trends Neurosci 28:364-370.
9. Harsing LG Jr and Zigmond MJ (1997) Influence of dopamine on GABA release in striatum: evidence for D1-D2 interactions and non-synaptic influences. Neuroscience 77:419-429.
10. Hikosaka O, Takikawa Y and Kawagoe R (2000) Role of the basal ganglia in the control of purposive saccadic eye movements. Physiol Rev 80:953-978.
11. Horvitz JC, Williams G and Joy Rekha R (2001) Time-dependent actions of D2 family agonist quinpirole on spontaneous behavior in the rat: dissociation between sniffing and locomotion. Psychopharmacology (Berl) 154:350-355.
12. Mazurski EJ and Beninger RJ (1991) Effects of selective drugs for dopaminergic D1 and D2 receptors on conditioned locomotion in rats. Psychopharmacology (Berl) 105:107-112.
13. Mink JW (1996) The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 50:381-425.
14. Molloy AG and Waddington JL (1987) Assessment of grooming and other behavioural responses to the D1 dopamine receptor agonist SK&F 38393 and its R- and S-enantiomers in the intact adult rat. Psychopharmacology (Berl) 92:16-168.
15. Molloy AG and Waddington JL (1985) Sniffing, rearing and locomotor responses to the D1 dopamine agonist R-SK&F 38393 and to apomorphine: Differential interactions with the selective D1 and D2 antagonists SCH 23390 and metoclopramide. Eur J Pharmacol 108:305-308.

16. Percheron G, Fénelon G and Leroux-Hugon V and Fève A (1994) History of the basal ganglia system. Slow development of a major cerebral system. Rev Neurol (Paris) 150:543-554.

17. Redgrave P, Rodriguez M, Smith Y, Rodriguez-Oroz MC, Lehericy S, Bergman H, Agid Y, DeLong MR and Obeso JA (2010) Goal-directed and habitual control in the basal ganglia: implications for Parkinson’s disease. Nat Rev Neurosci 11:760-772.

18. Schindler CW and Carmona GN (2002) Effects of dopamine agonists and antagonists on locomotor activity in male and female rats. Pharmacol Biochem Behav 72:857-863.

19. Steg G and Johnels B (1993) Physiological mechanisms and assessment of motor disorders in Parkinson’s disease. Adv Neurol 60:358-365.

20. Stuchlik A, Rehakova L, Rambousek L, Svoboda J and Vales K (2007) Manipulation of D2 receptors with quinpirole and sulpiride affects locomotor activity before spatial behavior of rats in an active place avoidance task. Neurosci Res 58:133-139.

21. Yelnik J, François C, Percheron G and Tandé D (1991) Morphological taxonomy of the neurons of the primate striatum. J Comp Neurol 313:273-294.